Quick answers
- What is Eteplirsen used for?
- The FDA-approved label (Exondys 51, Sarepta Therapeutics, Inc., August 13, 2025) says: “EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Eteplirsen have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Eteplirsen?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Eteplirsen been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Eteplirsen?
- 1 company lists prescription products of Eteplirsen in the FDA NDC Directory, including Sarepta Therapeutics, Inc..
What Eteplirsen is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 […]. …
— FDA label: Exondys 51, Sarepta Therapeutics, Inc., effective August 13, 2025. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Injection |
|---|---|
| Route | Intravenous |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Exondys 51 |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Sarepta Therapeutics, Inc.2 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA206488 EXONDYS 51 | Sarepta Theraps Inc | September 19, 2016 | 8, latest December 27, 2024 2024: Labeling · 2022: Labeling · 2022: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1810573, 1810578, 1810581, 1810582 |
|---|---|
| SPL set ID of the quoted label | 33bff678-7829-479e-9110-b8e33a0bc0aa |
| FDA labels (SPL) | 1 |
| FDA applications | NDA206488 |
| Active ingredients (FDA) | ETEPLIRSEN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Exondys 51, Sarepta Therapeutics, Inc., effective August 13, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →